Sign In
Buy TRIB
$11.60
-1.15 (-9.02%)
At Close: Jul 31, 2026
Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
07:30am, Wednesday, 22'nd Jul 2026
- Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develo
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
07:15am, Wednesday, 22'nd Jul 2026
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) repre
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech's CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows
- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by 2033 1
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
03:15pm, Monday, 29'th Jun 2026
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressi
- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
09:10am, Tuesday, 16'th Jun 2026
– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
09:27am, Friday, 01'st May 2026
- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transf
Trinity Biotech (TRIB) to Release Earnings on Wednesday
01:08am, Wednesday, 01'st Apr 2026
Trinity Biotech (NASDAQ: TRIB - Get Free Report) is expected to release its Q4 2025 resultson Wednesday, April 8th. Analysts expect Trinity Biotech to post earnings of ($0.32) per share and revenue of
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
09:23am, Monday, 23'rd Mar 2026
DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a global diagnostics company, today announced successful results from a clinical study of a new, enhanced ve
CompuMed (OTCMKTS:CMPD) & Trinity Biotech (NASDAQ:TRIB) Head-To-Head Review
02:30am, Sunday, 22'nd Mar 2026
Trinity Biotech (NASDAQ: TRIB - Get Free Report) and CompuMed (OTCMKTS:CMPD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on th
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome
08:30am, Wednesday, 18'th Mar 2026
DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, inc
Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech p
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
09:00am, Wednesday, 11'th Mar 2026
DUBLIN and WILSONVILLE, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solut
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
07:55am, Tuesday, 10'th Mar 2026
- Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronic
